Angela R Branche1, Lisa Saiman2,3, Edward E Walsh1,4, Ann R Falsey1,4, William D Sieling2, William Greendyke5, Derick R Peterson6, Celibell Y Vargas2, Matthew Phillips7, Lyn Finelli7. 1. Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, New York, USA. 2. Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA. 3. Department of Infection Prevention and Control, New York-Presbyterian Hospital, New York, New York, USA. 4. Rochester General Hospital, Rochester, New York, USA. 5. Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA. 6. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA. 7. Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) causes acute respiratory illness (ARI) and triggers exacerbations of cardiopulmonary disease. Estimates of incidence in hospitalized adults range widely, with few data on incidence in adults with comorbidities that increase the risk of severity. We conducted a prospective, population-based, surveillance study to estimate incidence of RSV hospitalization among adults overall and those with specific comorbidities. METHODS: Hospitalized adults aged ≥18 years residing in the surveillance area with ≥2 ARI symptoms or exacerbation of underlying cardiopulmonary disease were screened during the 2017-2018, 2018-2019, and 2019-2020 RSV seasons in 3 hospitals in Rochester, New York and New York City. Respiratory specimens were tested for RSV using polymerase chain reaction assays. RSV incidence per 100 000 was adjusted by market share. RESULTS: Active and passive surveillance identified 1099 adults hospitalized with RSV. Annual incidence during 3 seasons ranged from 44.2 to 58.9/100 000. Age-group-specific incidence ranged from 7.7 to 11.9/100 000, 33.5 to 57.5/100 000, and 136.9 to 255.6/100 000 in patients ages 18-49, 50-64, and ≥65 years, respectively. Incidence rates in patients with chronic obstructive pulmonary disease, coronary artery disease, and congestive heart failure were 3-13, 4-7, and 4-33 times, respectively, the incidence in patients without these conditions. CONCLUSIONS: We found a high burden of RSV hospitalization in this large prospective study. Notable was the high incidence among older patients and those with cardiac conditions. These data confirm the need for effective vaccines to prevent RSV infection in older and vulnerable adults.
BACKGROUND: Respiratory syncytial virus (RSV) causes acute respiratory illness (ARI) and triggers exacerbations of cardiopulmonary disease. Estimates of incidence in hospitalized adults range widely, with few data on incidence in adults with comorbidities that increase the risk of severity. We conducted a prospective, population-based, surveillance study to estimate incidence of RSV hospitalization among adults overall and those with specific comorbidities. METHODS: Hospitalized adults aged ≥18 years residing in the surveillance area with ≥2 ARI symptoms or exacerbation of underlying cardiopulmonary disease were screened during the 2017-2018, 2018-2019, and 2019-2020 RSV seasons in 3 hospitals in Rochester, New York and New York City. Respiratory specimens were tested for RSV using polymerase chain reaction assays. RSV incidence per 100 000 was adjusted by market share. RESULTS: Active and passive surveillance identified 1099 adults hospitalized with RSV. Annual incidence during 3 seasons ranged from 44.2 to 58.9/100 000. Age-group-specific incidence ranged from 7.7 to 11.9/100 000, 33.5 to 57.5/100 000, and 136.9 to 255.6/100 000 in patients ages 18-49, 50-64, and ≥65 years, respectively. Incidence rates in patients with chronic obstructive pulmonary disease, coronary artery disease, and congestive heart failure were 3-13, 4-7, and 4-33 times, respectively, the incidence in patients without these conditions. CONCLUSIONS: We found a high burden of RSV hospitalization in this large prospective study. Notable was the high incidence among older patients and those with cardiac conditions. These data confirm the need for effective vaccines to prevent RSV infection in older and vulnerable adults.
Authors: Angela R Branche; Lisa Saiman; Edward E Walsh; Ann R Falsey; Haomiao Jia; Angela Barrett; Luis Alba; Matthew Phillips; Lyn Finelli Journal: Influenza Other Respir Viruses Date: 2022-09-07 Impact factor: 5.606
Authors: John M McLaughlin; Farid Khan; Elizabeth Begier; David L Swerdlow; Luis Jodar; Ann R Falsey Journal: Open Forum Infect Dis Date: 2022-06-17 Impact factor: 4.423
Authors: Yoonyoung Choi; Alexandra Hill-Ricciuti; Angela R Branche; William D Sieling; Lisa Saiman; Edward E Walsh; Matthew Phillips; Ann R Falsey; Lyn Finelli Journal: Influenza Other Respir Viruses Date: 2021-10-03 Impact factor: 4.380